Bertis
- Bertis develops early detection technologies
for cancer and other major diseases. - Since its foundation in 2014, Bertis has been conducting the most advanced quantitative proteomics studies.
The company establishes a foundation for precision medicine by developing diagnostic solutions based on technology that combines proteomics and AI.
-
Multi-omics, leading the Bio 3.0 era
Proteomics + Artificial Intelligence
As a biotechnology company, Bertis focuses on proteomics-based molecular diagnostics. We discover biomarkers for different major diseases by combining AI with high-performance mass spectrometry technology, which allows us to quantify extremely small amounts of protein. 
-
Breast cancer, the cancer with the highest incidence in women worldwide
An innovative screening method that can overcome the limitations of existing screening methods
Every year an estimated 1.7 million people are diagnosed as breast cancer, and these kinds of incidence rates in Asian countries, including Korea and China, are rising rapidly. However, there is a great need for an alternative screening method to overcome the limitations of diagnostic imaging, the current standard. MASTOCHECK is an innovative screening method for early detection. It can diagnose breast cancer with only 1 ml of blood, even stage 1 cancer that is difficult to identify with other screening methods. 
- We value human dignity and self-esteem and
contribute to family happiness and society - One drop of blood opens the new medical era of "diagnosis" and "prevention."
Bertis is here to guide your way to the new paradigm.